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Abstract
The Philadelphia chromosome is observed in 5% of pediatric acute lymphocytic leukemia (ALL) and in 25% to 50% of
adult ALL cases, and is associated with poor prognosis. Double Ph in a hyperdiploid karyotype is common in chronic
myeloid leukemia (CML), but rarely found in ALL. We report here the case of a girl diagnosed with ALL at 7 years of
age. After treatment with the pediatric protocol BFM 83 for ALL, she stayed in continuous complete remission for nine
years. At age 19, she was re-admitted with a white blood cell count of 6.8 x 109/L with 3% blasts, and a platelet count
of 65 x 109/L. Bone marrow aspirate showed 92.6% lymphoid blast cells, and chromosome analysis after G-banding
revealed the karyotype 51,XX,+?5,t(9;22)(q34.1;q11.2),+16,+20,+21,+der(22)t(9;22)(q34.1;q11.2)[10]/46,XX[1].
FISH analysis for the BCR/ABL fusion showed 56% of interphase cells with two fusion signals, 30% with one, and 6%
with three. Double Ph is rare in relapsed leukemia, and the possibility of secondary leukemia cannot be ruled out.
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Introduction
The Philadelphia (Ph) chromosome, the hallmark ge-
netic lesion of chronic myeloid leukemia (CML), is less fre-
quently found in acute lymphocytic leukemia (ALL) and
rarely in acute myelogenous leukemia (AML). It is present
in only 5% of the pediatric and 25% to 50% of the adult
ALL cases, and is associated with poor prognosis (Secker-
Walker et al., 1991). Additional cytogenetic aberrations are
described in 41% to 86% of patients with Ph+ ALL. A
hyperdiploid karyotype, defined by the presence of more
than 50 chromosomes, is detected in 2% to 9% of adult
ALL patients and in 29% of pediatric patients (Ritterbach et
al., 1998; Wetzler et al., 2000). Translocation t(9;22) is a
common structural aberration found in patients with hyper-
diploidy (37% and 64%, respectively) (The Groupe Fran-
çais de Cytogénétique Hématologique, 1996; Faderl et al.,
2000).
The BCR/ABL breakpoint varies according to the
type of leukemia. CML is almost always associated with
the p210BCR/ABL variant. In pediatric Ph+ ALL, nearly 90%
of cases have the p190 variant, but in adult ALL approxi-
mately 25% to 50% of cases are p210BCR/ABL (Secker-
Walker et al., 1991). In fact, the so-called Ph+ ALL seems
to be a heterogeneous disease including: (1) lymphoid lin-
eage-restricted ALL that can be either p190 or p210BCR/ABL,
although most cases have been p190BCR/ABL, (2) stem cell
ALL, with evidence of disease in both lymphoid and
myeloid lineages, that can either be p190 or p210BCR/ABL,
(3) misclassified CML in lymphoid blast crisis, which is a
stem cell disease and mainly p210BCR/ABL (Radich et al.,
2001).
We report a case of relapsed ALL associated with
double Philadelphia chromosome in a patient who had been
diagnosed with ALL at 7 years of age and had stayed in re-
mission for nine years.
Case Report
A 7-year-old girl was admitted to HSP/UNIFESP in
October 1989 with widespread adenopathy and weight loss.
On physical exam she showed submandibular, cervical,
axilar and inguinal adenopathies, besides splenomegaly.
Peripheral blood tests revealed 8.4 g/dL of hemoglobin, a
white blood cell count of 28.6 x 109/L with 78% blast cells,
and a platelet count of 90 x 109/L. Bone marrow aspirate
was hypercellular, with 90% blast cells of the FAB L2 sub-
type, and peroxidase-negative. Immunophenotyping
showed CD19+, CD10+, CD13- and CD33-. The patient
was treated according to the children ALL BFM 83 proto-
col (Riehn. et al., 1990), and achieved complete remission
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after induction. She completed the whole protocol by May
1992 and stayed nine years out of treatment. In November
2001, at the age of 19, she was admitted complaining of leg
pain, echimosis, fever, and anorexia. There were no abnor-
mal physical findings other than echimosis. Peripheral
blood tests revealed 12.3 g/dL of hemoglobin, a white
blood cell count of 6.8 x 109/L with 3% blasts, and a platelet
count of 65 x 109/L. Bone marrow aspirate was hyper-
cellular, with 92.6% lymphoblasts, which were morpholog-
ically similar to those observed at the first diagnosis, and
were peroxidase-negative. Flow cytometry immunopheno-
typing showed: CD10+, CD19+, CD13+, CD33+. Cyto-
plasm and surface immunoglobulins were negative. Chro-
mosome analysis revealed a 51,XX,+?5,t(9;22)(q34.1;
q11.2),+16,+20,+21,+der(22)t(9;22)(q34.1;q11.2)[10]/46,
XX[1] karyotype. RT-PCR showed the p190BCR/ABL vari-
ant. FISH performed for the BCR/ABL rearrangement
showed 56% of cells with two BCR/ABL fusion signals,
30% with one signal, and 6% with three signals (200
interphase cells were counted by each of two observers).
The patient was treated with Prednisone (D1-21),
Vincristine (D1, 8, 15), Daunorubicine (D1, 8, 15), and
L-asparaginase (D7-8, D14-15). A bone marrow aspirate
performed on day 14 after induction had 71% blasts, and
she was scheduled for the Hyper-CVAD regimen (Gar-
cia-Manero et al., 2000). In spite of the treatment, she de-
veloped hepatosplenic candidiasis and cerebellar toxicity
probably due to cytarabine, and died in sepsis without re-
mission in February 2002.
Discussion
We describe here the rare case of a young female pa-
tient with double Ph chromosome and ALL diagnosed
twelve years after the first ALL diagnosis, and after nine
years of complete remission. The main question is whether
her leukemia was secondary to the treatment received
twelve years earlier or a true relapsed leukemia.
Patients with Ph chromosomes treated only with con-
ventional chemotherapy have a poor long-term survival.
Although 72% to 97% of the pediatric Ph+ cases achieve
complete remission (CR) after induction therapy, the
5-year event-free survival (EFS) ranges from 10% to 20%,
vs. 76% in the Ph-negative population. Failure is due
mainly to recurrent disease, and the poor prognosis persists
after stratification in a high-risk treatment protocol. In adult
ALL, the CR rate of Ph+ patients is generally similar to that
of Ph-negative patients (60% to 80%). Nevertheless, the
duration of remission is usually shorter (<12 months) and
forces the EFS rate towards 10%, vs. 28% to 39% for the
whole group of adult ALL (Garcia-Manero et al., 2000;
Radich et al., 2001).
Hyperdiploid karyotypes with double Ph are common
in CML, with over five hundred reported cases. In contrast,
they are rare in ALL, and a total of 66 cases with double Ph
are reported in Mitelman’s Catalog of Chromosome Aber-
rations in Cancer (http://cgap.nci.nih.gov/Chromosomes/
CytSearchForm). Of those, only 23 were associated with
hyperdiploidy and, interestingly, only three patients
showed more than two copies of the Ph chromosome on
conventional karyotyping. In a series of 66 karyotypes of
Ph+ ALL patients, Rieder et al. (1996) found eight cases
with double Ph (12%), but only three (9%) were
hyperdiploid. Therefore, since Ph+ cases represent approx-
imately 25% of ALL, cases with double Ph should repre-
sent a smaller percentage of adult ALL. Thomas et al.
(1998) found seven cases of double Ph in 41 Ph+ ALL
(17%), and the presence of an extra Ph chromosome was
considered an initial parameter associated with a statisti-
cally significant worse prognosis. Uckun et al. (1998) stud-
ied 1,322 children with ALL, and found 30 Ph+ patients,
four of whom had double Ph, corresponding to 13% of Ph+
ALL and to 0.03% of pediatric ALL.
It has been recognized that ALL shows significant
immunophenotypic and karyotypic diversity. Moreover,
ALL patients frequently undergo karyotype and immuno-
phenotype changes at the time of relapse. Clonal evolution
is not the only cytogenetic observation at relapse; some
cases show entirely different karyotypes, thereby raising
the possibility of secondary leukemia (Raimondi SC,
1993). Chucrallah et al. (1995) analyzed 32 relapsed adult
ALL patients and found that nine (28%) had clonal evolu-
tion, 12 (37%) had a different karyotype, and 11 (34%) had
an unchanged karyotype.
FISH analysis performed in the present case showed
the double BCR/ABL fusion signals in the majority of
interphase cells, and rare cells with three fusion signals.
Unfortunately, FISH could not be performed on marrow
smear from the first diagnosis stored in a common file at
room temperature, and thus it was not possible to clarify if
the patient was Ph+ at first diagnosis. However, this possi-
bility is unlikely, because the patient stayed in remission
and out of treatment for nine years following conventional
chemotherapy, whereas the outcome of Ph+ ALL cases is
highly unfavorable. Although the phenotype change (ac-
quired CD13 and CD33) and the probably acquired Ph+ fa-
vor the hypothesis of a secondary leukemia, the doubt
remains whether the second disease could be a relapsed
ALL with clone evolution.
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